Larry Schlesinger S MD

Larry Schlesinger S MD
ChairCollege of Medicineschlesinger.17@osu.edu
798 Biomedical Research Tower 460 W 12th Avenue Columbus Ohio 43210
Phone:614-292-8789Fax:
  • Non-Member

Research Description

Dr. Schlesinger’s research focuses on innate immunity in mycobacterial and Francisella infections by studying human mononuclear phagocyte interactions with pathogenic mycobacteria, particularly M. tuberculosis and F. tularensis.  The laboratory uses a variety of approaches (cell biology, immunology, molecular biology and biochemistry) to study the role of microbial surface glycoconjugates in complement activation and in binding to phagocyte receptors.  It also focuses on the mechanism of phagocytosis of microbes by macrophages, the intracellular signaling and trafficking pathway of microbial products and the ability of intracellular pathogens to regulate the biosynthesis and expression of macrophage class II molecules, accessory molecules for antigen presentation and molecules involved in cellular adhesion.  The laboratory uses novel in-vitro models that include surfactant components to study innate immune responses to these pathogens in the air spaces of the lung.  Newly characterized clinical isolates of bacteria and mutant strains of bacteria are used. New scientific platforms include glycomics and lipidomics with the goal to identify novel therapeutic targets against infectious agents.

Transinstitutional Work

Dr. Schlesinger is director of the Division of Infectious Diseases and founding director of the OSU Center for Microbial Interface Biology (CMIB), a Board of Trustees’ approved campus wide research and education Center, focused on infectious diseases, microbial pathogenesis and biodefense. There are 11 core faculty members in the CMIB with a total of 70 members from six colleges that are performing interdisciplinary, cutting edge research using a variety of scientific platforms. Dr. Schlesinger is also chair of the steering committee for the Provost-initiated Targeted Investment in Excellence (TIE) program called “Public Health Preparedness for Infectious Diseases” that includes 125 faculty for the Colleges of Medicine, Veterinary Medicine, Public Health, Pharmacy, Biological, Math and Physical sciences and Food, Agricultural and Environmental Sciences. Dr. Schlesinger’s research programs include a variety of partners such as those in the CCC, Heart & Lung Research Institute, Nationwide Children’s hospital and Research Institute, the OARDC, Columbus Public Health and Battelle.  

Current Publications

  • Young NA, Wu LC, Burd CJ, Friedman AK, Kaffenberger BH, Rajaram MV, Schlesinger LS, James H, Shupnik MA, Jarjour WNEstrogen modulation of endosome-associated toll-like receptor 8: an IFNα-independent mechanism of sex-bias in systemic lupus erythematosus.Clin Immunol 151 66-77 3/1/2014
  • Rajaram MV, Schlesinger LS, Azad AKExploitation of the Macrophage Mannose Receptor (CD206) in Infectious Disease Diagnostics and Therapeutics.J Cytol Mol Biol 1 1/10/2014
  • Young NA, Friedman AK, Kaffenberger B, Rajaram MV, Birmingham DJ, Rovin BH, Hebert LA, Schlesinger LS, Wu LC, Jarjour WNNovel estrogen target gene ZAS3 is overexpressed in systemic lupus erythematosus.Mol Immunol 54 23-31 5/1/2013
  • Caution K, Akhter A, Abdulrahman BA, Tazi M, Hassan H, Majumdar N, Doran A, Schlesinger LS, Shuman H, Amer AO, Khweek AA, Guirado EA bacterial protein promotes the recognition of the Legionella pneumophila vacuole by autophagy.Eur J Immunol 43 1333-44 5/1/2013
  • Gomez DI, Twahirwa M, Schlesinger LS, Restrepo BIReduced Mycobacterium tuberculosis association with monocytes from diabetes patients that have poor glucose control.Tuberculosis (Edinb) 93 192-7 3/1/2013
  • Azad AK, Curtis A, Papp A, Webb A, Knoell D, Sadee W, Schlesinger LSAllelic mRNA expression imbalance in C-type lectins reveals a frequent regulatory SNP in the human surfactant protein A (SP-A) gene.Genes Immun 14 99-106 3/1/2013
  • Shao G, Schlesinger LS, Huang Q, Cosmar DG, Bhatt NY, Culver DA, Baughman RP, Wood KL, Crouser ED, Julian MWNicotine treatment improves Toll-like receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis.Chest 143 461-70 2/1/2013
  • Guirado E, Schlesinger LSModeling the Mycobacterium tuberculosis Granuloma - the Critical Battlefield in Host Immunity and Disease.Front Immunol 4 98 1/1/2013
  • Dai S, Rajaram MV, Curry HM, Leander R, Schlesinger LSFine tuning inflammation at the front door: macrophage complement receptor 3-mediates phagocytosis and immune suppression for Francisella tularensis.PLoS Pathog 9 e1003114 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu